Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROJAN-C: Epclusa in HCV-negative heart transplant recipients from HCV-positive donors
NCT03383419Phase 2Recruiting
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Mar 2018
- Primary completion
- Dec 2026
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of velpatasvir in hepatitis C (HCV), sponsored by Baylor Scott & White Research Institute. Started Mar 2018; status: recruiting.
02
Drugs
velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03383419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03383419.